舒尼替尼致不良反应文献分析

Literature analysis of adverse effects induced by sunitinib

目的:分析舒尼替尼所致药品不良反应(ADR),为其临床安全用药提供参考。方法:检索2006—2021年6个中英文数据库关于舒尼替尼致不良反应的文献报道,提取相关数据,并进行统计分析。结果:共纳入文献147篇,涉及156例患者,283例次不良事件。不良反应发生在给药31~180 d的比率最高,ADR累及器官/系统以血液及淋巴系统(17.67%)、胃肠系统(15.55%)、皮肤及皮下组织类(10.60%)为主。结论:舒尼替尼所致的不良反应累及全身多个器官/系统,不乏严重致死病例。在临床用药期间应定期监测患者情况,在发生不良反应时及时减少或停止给药,以降低临床用药风险。

Objective:To analyze the adverse drug reactions(ADRs)associated with sunitinib and to provide references for the clinical medication.Methods:ADRs of sunitinib published were searched in six databases in languages of Chinese and English from 2006 to 2021,and the relevant data was extracted for statistical analysis.Results:A total of 147 articles were included,involving 156 patients and 283 adverse events.The ADRs of sunitinib frequently occurred after 31 to 180 days of medication,and mainly mainfested as blood and lymphatic disorders(17.67%),gastrointestinal disorders(15.55%)and skin and subcutaneous tissue disorders(10.60%).Conclusion:The ADRs of sunitinib involve multiple organs/systems and may cause serious fatal cases.Patients should be monitored regularly during clinical medication.The administration of the drug should be reduced in dose or stopped in time when the adverse reactions occur,to reduce the risk of clinical medication.